In The News
-Sathish Raman
Anneo Biotech is an India-based manufacturer with Bacillus clausii, Bacillus coagulans and fructo-oligosaccharides (FOS) as its flagship ingredient lines. The company is developing its growth around fermentation, microbial manufacturing and nutritional innovation, connecting established ingredients with opportunities emerging from microbiome research.
Anneo Biotech is pioneering India’s manufacturing of probiotics, prebiotics, and microbiome wellness ingredients. Discover their flagship Bacillus clausii, Bacillus coagulans, and FOS lines, driving nutritional innovation. The company focuses on dependable supply, technical collaboration, and R&D to meet global health demands, including exploring HMOs and new prebiotic sweeteners.
Its work addresses two closely linked needs. Nutrition businesses require dependable ingredients, consistent manufacturing and technical support. Consumers want products that fit their routines and offer benefits they can understand. Bringing those needs together requires scientific judgement, careful formulation and attention to how a product performs beyond the laboratory.
For Anneo, its Clausii, Coagulans and FOS lines provide a foundation from which to build customer relationships, develop additional applications and pursue new nutritional ingredients.
A global opportunity shaped by everyday health concerns
The growing interest in probiotics reflects a change in how people think about wellbeing. Digestive comfort, food choices and the relationship between gut health and daily life are receiving greater attention. Nutrition companies are responding with products intended for different age groups, preferences and delivery formats.
The commercial opportunity is substantial. A Euromonitor analysis prepared for the International Probiotics Association estimated global probiotic supplement retail sales at approximately US$9 billion in 2023, forecasting annual growth of 7% for 2024–2028. These figures cover supplements specifically, rather than the entire market for probiotic foods and ingredients.
For manufacturers, growing demand brings higher expectations. Customers increasingly need to understand the identity of an ingredient, the evidence supporting its application and the conditions under which it will remain stable.
Anneo’s opportunity lies in meeting those expectations through dependable supply and informed technical collaboration. A successful customer relationship can begin with a sample, but it develops through consistent performance across subsequent batches and finished formulations.
Three flagship lines, a connected growth direction
Bacillus clausii and Bacillus coagulans form the core of Anneo’s probiotic manufacturing identity, while FOS anchors its prebiotic line. Together, they give the company a presence across two distinct areas of nutritional biotechnology.
That distinction is important. Probiotics are live microorganisms demonstrated to provide a health benefit when administered in adequate amounts. Prebiotics are substances selectively used by microorganisms in ways that confer a health benefit. The effects depend on the particular strain or ingredient, its dose and the intended application.
Working across both categories creates opportunities to support individual ingredient requirements and explore complementary formulations. Each application still requires its own technical assessment, including the relevant specification, formulation conditions and supporting evidence.
Anneo’s growth direction therefore extends from manufacturing ingredients to helping customers understand how to use them effectively.
“Our vision is to build Anneo into a dependable Indian biotechnology manufacturer serving customers in India and overseas. We want to strengthen our flagship ingredients while investing in the people, processes and research capabilities that allow us to develop the next generation of nutritional products.” — Mr. Vasanth JB, Director.
Investing in the work behind the ingredient
Research and development in biotechnology often advances through detailed, patient work. A formulation may need several revisions. A fermentation process may perform differently as production increases. An ingredient that meets its initial specification must also be assessed in the environment in which a customer intends to use it.
Anneo’s stated research priorities include strain characterisation, fermentation process development, stability and formulation adaptability. The company also describes a commitment of resources to scientific advancement and innovation.
Investment in these areas supports the practical foundations of growth: skilled scientific teams, better process understanding, suitable analytical capabilities and carefully designed validation programmes.
For a manufacturer, this work can improve the consistency of existing products while informing decisions about new ones. It also helps establish which applications are ready to progress and which require further development.
The commercial value becomes visible when research translates into a repeatable process, a clearer specification or a formulation that performs more reliably for a customer.
Precision biotics: developing with a clearer purpose
The significance of precision biotics lies in a more targeted approach to ingredient development. It begins with a defined application and asks which biological ingredient, dose and formulation are appropriate for that purpose.
This requires looking beyond a species name or a high microbial count. Probiotic benefits depend on the specific strain and supporting evidence, making identity and documentation essential parts of product development.
For Anneo, precision biotics offers a useful direction for future research and collaboration. It encourages development teams to connect biological understanding with manufacturing requirements and the realities of the finished product.
The questions are practical: Will the ingredient remain viable during storage? Is it compatible with the other components? Can the manufacturing process deliver consistent quality? Does the available evidence fit the proposed use?
Answering those questions carefully can help create products with a clearer purpose and give commercial partners a stronger basis for development.
Exploring HMOs for India
Human milk oligosaccharides, or HMOs, represent another developing area of
microbiome-related nutrition. These complex carbohydrates occur naturally in human milk, and selected HMOs are also being developed as nutritional ingredients.
India has seen progress in this category. In 2025, dsm-firmenich announced FSSAI approval for its specific 2′-FL HMO ingredient for defined early-life nutrition applications. This
product-specific milestone illustrates the field’s developing commercial relevance in India.
For Anneo’s longer-term direction, HMOs offer an opportunity to evaluate research partnerships, technical feasibility and potential manufacturing or sourcing models. Progress would require appropriate safety evidence, product specifications and the regulatory pathway applicable to the intended use.
It is an area where scientific collaboration can be particularly valuable, allowing a company to assess the opportunity carefully before making commercial commitments.
“We want Anneo to grow through a strong research culture and disciplined execution. Our direction is to deepen our flagship manufacturing capabilities, invest in scientific talent and validation, and pursue new ingredients where we can establish both technical credibility and a practical customer need.”, Mr. Venkateshwaran Srinivasan, Director.
Bringing prebiotic fibre innovation to the table
Anneo is also developing a prebiotic fibre tabletop sweetener, positioning it as an alternative to conventional sugar and standard tabletop sweeteners.
The initiative brings the company’s prebiotic interests into a familiar part of everyday life. A tabletop product has to work in ordinary situations: a morning beverage, food prepared at home or a routine followed over many months.
Its acceptance will depend on details that consumers notice immediately. Taste, aftertaste, dissolution, texture, ease of handling and price all influence whether someone chooses to use a product again.
The development aims to combine sweetness with fibre ingredients in a convenient format. Formulation work must also address consistency during storage and the contribution of ingredients at realistic serving sizes. The final nutritional composition and product claims will be established through validation.
For Anneo, this creates an opportunity to connect ingredient manufacturing with a recognisable consumer need. Its flagship probiotic and FOS lines provide the manufacturing foundation; continued research and product development can help extend that foundation into new applications for everyday nutrition.
